Vildagiliptininin Diyabetik Nefropatili Hastalarda Etkilerinin Değerlendirilmesi

Aim: When kidney failure occurs the treatment choices for diabetes is narrowed. To evaluate the effect of vildagliptin, a DPP-4 inhibitor, in diabetic nephropathy patients we planned this study. Patients and methods: Twenty two patients (15 M, 7 F, mean age 59,3 + 7,4) admitted to our outpatient clinics within past two and half years with type 2 diabetes mellitus, more than 300 mg/g albuminuria, GFR less than 60 ml/min and started vildagliptin were evaluated retrospectively. Results: After 3 months of vildagliptin treatment HbA1c is tended to be reduced (basal 8,3±1,7; after 3 month: 7,7±1,6; p=0,08 ), eGFR (basal 45,7±19,8 ml/min; after 3 month:44,9±20,1 ml/min; p=0,57) and albuminuria (basal 1572,1 mg/G ± 1829,5; after 3 mo; 1590,1±1936,9; p=0,84) did not changed. Other parameters including